RMDA Stock Overview
Produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م4.56 |
| 52 Week High | ج.م4.88 |
| 52 Week Low | ج.م1.85 |
| Beta | 0.26 |
| 1 Month Change | 2.01% |
| 3 Month Change | 31.79% |
| 1 Year Change | 130.30% |
| 3 Year Change | 208.57% |
| 5 Year Change | 128.68% |
| Change since IPO | 103.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| RMDA | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -3.0% | -0.1% | -2.6% |
| 1Y | 130.3% | 53.3% | 30.8% |
Return vs Industry: RMDA exceeded the EG Pharmaceuticals industry which returned 52.9% over the past year.
Return vs Market: RMDA exceeded the EG Market which returned 31.9% over the past year.
Price Volatility
| RMDA volatility | |
|---|---|
| RMDA Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in EG Market | 8.3% |
| 10% least volatile stocks in EG Market | 3.1% |
Stable Share Price: RMDA has not had significant price volatility in the past 3 months compared to the EG market.
Volatility Over Time: RMDA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Amr Morsy | www.ramedapharma.com |
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. The company manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use, and diagnostic reagents for individuals, laboratories, and hospitals; imports pharmaceutical reagents and raw materials; and produces food supplements for human use. It offers a portfolio of products in various therapeutic areas, such as anti-biotics, cardiovascular diseases and gastro-intestinal tract disorders, anti-infectives, alimentary tract and metabolism, genito-urinary system, nervous system, blood forming organs, weight management, and sex hormones.
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Fundamentals Summary
| RMDA fundamental statistics | |
|---|---|
| Market cap | ج.م6.86b |
| Earnings (TTM) | ج.م363.84m |
| Revenue (TTM) | ج.م2.77b |
18.8x
P/E Ratio2.5x
P/S RatioIs RMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMDA income statement (TTM) | |
|---|---|
| Revenue | ج.م2.77b |
| Cost of Revenue | ج.م1.49b |
| Gross Profit | ج.م1.28b |
| Other Expenses | ج.م917.63m |
| Earnings | ج.م363.84m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 46.28% |
| Net Profit Margin | 13.14% |
| Debt/Equity Ratio | 75.0% |
How did RMDA perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield38%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 18:57 |
| End of Day Share Price | 2025/05/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eman Maree | Arab African International Securities |
| Ahmed Rashad | Beltone Financial |
| Marina Mikhail | CI Capital Research |